New strategy aims to boost chemo power in childhood leukemia

NCT ID NCT03164057

Ongoing Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether giving a short course of azacitidine or decitabine before standard chemotherapy can improve outcomes for children with newly diagnosed acute myeloid leukemia (AML). The study enrolls 206 participants and focuses on tolerability, changes in DNA methylation, and survival. The goal is to see if this 'epigenetic priming' approach can reduce minimal residual disease and improve event-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Azacitidine or Decitabine (epigenetic priming drugs given before standard chemotherapy)
What this could lead to: If successful, this approach could improve survival and reduce relapse in children with newly diagnosed acute myeloid leukemia by making chemotherapy more effective.
What could go wrong: This is a phase II trial, so results are preliminary. The added drugs may cause more side effects, and it's unclear if they will meaningfully improve outcomes compared to standard treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes myeloid sarcoma therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Children's Hospital of Central California

Madera, California, 93636, United States
Children's Hospital of Michigan

Detroit, Michigan, 48201, United States
Children's Hospital of Orange County

Orange, California, 92968, United States
Cook Children's Medical Center

Fort Worth, Texas, 76104, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Lucile Packard Children's Hospital Stanford University

Palo Alto, California, 94304, United States
Rady Children's Hospital and Health Center

San Diego, California, 92123, United States
Sanford Children's Specialty Clinic

Sioux Falls, South Dakota, 57117, United States
St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States
University of Chicago Children's Hospital (Comer)

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.